Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAFV600E or wild-type …
ZA Antonello, C Nucera - Oncogene, 2014 - nature.com
Molecular signature of advanced and metastatic thyroid carcinoma involves deregulation of
multiple fundamental pathways activated in the tumor microenvironment. They include BRAF …
multiple fundamental pathways activated in the tumor microenvironment. They include BRAF …
The Next Generation of Orthotopic Thyroid Cancer Models: Immunocompetent Orthotopic Mouse Models of BRAFV600E-Positive Papillary and Anaplastic Thyroid …
P Vanden Borre, DG McFadden, V Gunda, PM Sadow… - Thyroid, 2014 - liebertpub.com
Background: While the development of new treatments for aggressive thyroid cancer has
advanced in the last 10 years, progress has trailed headways made with other …
advanced in the last 10 years, progress has trailed headways made with other …
[HTML][HTML] Mouse models as a tool for understanding progression in BrafV600E-driven thyroid cancers
I Landa, JA Knauf - Endocrinology and Metabolism, 2019 - synapse.koreamed.org
The development of next generation sequencing (NGS) has led to marked advancement of
our understanding of genetic events mediating the initiation and progression of thyroid …
our understanding of genetic events mediating the initiation and progression of thyroid …
Late Intervention with anti-BRAFV600E Therapy Induces Tumor Regression in an Orthotopic Mouse Model of Human Anaplastic Thyroid Cancer
Human anaplastic thyroid cancer (ATC) is a lethal disease with an advanced clinical
presentation and median survival of 3 months. The BRAFV600E oncoprotein is a potent …
presentation and median survival of 3 months. The BRAFV600E oncoprotein is a potent …
[HTML][HTML] Combined BRAFV600E-and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic …
PV Borre, V Gunda, DG McFadden, PM Sadow… - Oncotarget, 2014 - ncbi.nlm.nih.gov
Anaplastic (ATC) and refractory papillary thyroid cancer (PTC) lack effective treatments.
Inhibition of either oncogenic BRAF or SRC has marked anti-tumor effects in mouse models …
Inhibition of either oncogenic BRAF or SRC has marked anti-tumor effects in mouse models …
Tissue architecture delineates field cancerization in BRAFV600E-induced tumor development
E Schoultz, E Johansson, C Moccia… - Disease models & …, 2022 - journals.biologists.com
Cancer cells hijack developmental growth mechanisms but whether tissue morphogenesis
and architecture modify tumorigenesis is unknown. Here, we characterized a new mouse …
and architecture modify tumorigenesis is unknown. Here, we characterized a new mouse …
A novel orthotopic mouse model of human anaplastic thyroid carcinoma
C Nucera, MA Nehs, M Mekel, X Zhang, R Hodin… - Thyroid, 2009 - liebertpub.com
Background: Orthotopic mouse models of human cancer represent an important in vivo tool
for drug testing and validation. Most of the human thyroid carcinoma cell lines used in …
for drug testing and validation. Most of the human thyroid carcinoma cell lines used in …
BRAFV600E Transduction of an SV40-Immortalized Normal Human Thyroid Cell Line Induces Dedifferentiated Thyroid Carcinogenesis in a Mouse Xenograft Model
M Kim, S Kim, Z Xu, SY Ha, JH Byeon, EJ Kang… - Thyroid, 2020 - liebertpub.com
Background: Despite active studies of the clinical importance of BRAFV600E, suitable
research models to investigate the role of this mutation in the etiopathogenesis of human …
research models to investigate the role of this mutation in the etiopathogenesis of human …
Targeted Expression of BRAFV600E in Thyroid Cells of Transgenic Mice Results in Papillary Thyroid Cancers that Undergo Dedifferentiation
JA Knauf, X Ma, EP Smith, L Zhang, N Mitsutake… - Cancer research, 2005 - AACR
The BRAFT1799A mutation is the most common genetic alteration in papillary thyroid
carcinomas (PTC). It is also found in a subset of papillary microcarcinomas, consistent with a …
carcinomas (PTC). It is also found in a subset of papillary microcarcinomas, consistent with a …
Targeting BRAFV600E with PLX4720 Displays Potent Antimigratory and Anti‐invasive Activity in Preclinical Models of Human Thyroid Cancer
Abstract Purpose. B‐RafV600E may play a role in the progression from papillary thyroid
cancer to anaplastic thyroid cancer (ATC). We tested the effects of a highly selective B …
cancer to anaplastic thyroid cancer (ATC). We tested the effects of a highly selective B …